DiagnosTear Ltd. – CE Mark Approval

Tel Aviv (April 16, 2019) – BioLight is pleased to announce that today, its subsidiary DiagnosTear Ltd. (“DiagnosTear“)[1], announced receipt of CE Mark approval for its product that is based on the TeaRx ™ technology, which is used to diagnose, personalize treatment and monitor Dry eye syndrome by examining the composition of the tear film (the “Product”  and the “Approval”).

[1] Holding via XL Vision Sciences Ltd. (wholly owned subsidiary) approx. 89% of the issued and share capital of Diagnostear (approx. 86% fully diluted).

Link to the complete article

Link to Newsroom

Comments are closed.